Evidence map›Paper›PMID 34540663›Full record

ReviewFrontiers in oncology2021

The Role of Exosomal miRNAs in Glioma: Biological Function and Clinical Application.

Yirizhati Aili, Nuersimanguli Maimaitiming, Yusufu Mahemuti, Hu Qin, Yongxin Wang, Zengliang Wang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. [Circ_EPHB4 regulates temozolomide sensitivity in glioma cells through the miR-424-5p/Wnt3 axis].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2025
    Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yirizhati AiliDepartment of Neurosurgery, The First Affiliated Hospital of Xinjiang Medical University, Xinjiang, China.
Nuersimanguli MaimaitimingDepartment of Oncology, The First Affiliated Hospital of Xinjiang Medical University, Xinjiang, China.
Yusufu MahemutiDepartment of Neurosurgery, The First Affiliated Hospital of Xinjiang Medical University, Xinjiang, China.
Hu QinDepartment of Neurosurgery, The First Affiliated Hospital of Xinjiang Medical University, Xinjiang, China.
Yongxin WangDepartment of Neurosurgery, The First Affiliated Hospital of Xinjiang Medical University, Xinjiang, China.
Zengliang WangDepartment of Neurosurgery, The First Affiliated Hospital of Xinjiang Medical University, Xinjiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gliomas are complex and heterogeneous central nervous system tumors with poor prognosis. Despite the increasing development of aggressive combination therapies, the prognosis of glioma is generally unsatisfactory. Exosomal microRNA (miRNA) has been successfully used in other diseases as a reliable biomarker and even therapeutic target. Recent studies show that exosomal miRNA plays an important role in glioma occurrence, development, invasion, metastasis, and treatment resistance. However, the association of exosomal miRNA between glioma has not been systemically characterized. This will provide a theoretical basis for us to further explore the relationship between exosomal miRNAs and glioma and also has a positive clinical significance in the innovative diagnosis and treatment of glioma.

Indexed as

biomarkersexosomesgliomamicroenvironmentmiRNA

Identifiers

PMID34540663
PMCPMC8442992

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.